Omero Benedicto, Poli-Neto, Jaime Eduardo, Cecílio Hallak, Julio Cesar, Rosa-e-Silva, José Alexandre de Souza Crippa


March 4, 2023


Endometriosis affects 5%-10% of women of reproductive age and is often associated with painful symptoms like dysmenorrhea, dyschezia, dyspareunia, and even non cyclical pain. The disease is diagnosed in at least 20% of women with dysmenorrhea and/or non-menstrual pelvic pain, reaching a prevalence of 50% pain among adolescents. There is an alignment among international societies3,4 that the pre- sumed diagnosis of this disease is enough to start clinical treatment. Moreover, there seems to be a consensus that first-line treatment should be hormonal contraceptives since the efficacy is similar to that of surgery but with lower complication rates and costs. However, these drugs are
effective in only approximately two-thirds of patients, have limited long-term efficacy and may occasionally lead to undesirable side effects. Additionally, there are serious limitations in the interpretation of clinical trials.


DOI: 10.1055/s-0042-1749430


Poli-Neto, O. B., Hallak, J. E. C., Rosa-e-Silva, J. C., & Crippa, J. A. D. S. (2022). Is it the Ideal Time to Start Prescribing Cannabis Derivatives to Treat Endometriosis-associated Pain?. Revista Brasileira de Ginecologia e Obstetrícia, 44, 449-451.